New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model

ChemBioChem

Volumn 6, Issue 6, 2005, Pages 1119-1125

  Renner, Steffen ^a   Ludwig, Verena ^a   Boden, Oliver ^a   Scheffer, Ute ^a   Göbel, Michael ^a   Schneider, Gisbert ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Chemoinformatics; Drug design; FRET; RNA; Virtual screening

Indexed keywords

ACEPROMAZINE; AMIDE; ANTIRETROVIRUS AGENT; ARGININAMIDE; CGP 40336A; CHLORPROMAZINE; NEW DRUG; RNA; TAT TAR RNA INTERACTION INHIBITOR; TRANSACTIVATION RESPONSE ELEMENT RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CATS3D METHOD; CHEMISTRY; CHEMOINFORMATICS; DNA RESPONSIVE ELEMENT; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; INFORMATION SCIENCE; MOLECULE; PHARMACOPHORE; PRIORITY JOURNAL; SQUID METHOD; VIRTUAL REALITY; VIRTUAL SCREENING; VIRUS REPLICATION;

ACEPROMAZINE; ANTI-HIV AGENTS; BINDING SITES; CHLORPROMAZINE; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE PRODUCTS, TAT; HIV-1; NUCLEIC ACID CONFORMATION; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20444493219     PISSN: 14394227     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbic.200400376     Document Type: Article

References (35)

1. Special journal issues on RNA as drug target: a) Biopolymers 2003, 70, 1-119;
2. b) ChemBioChem 2003, 4, 913-1106.
3. a) G. J. R. Zaman, P. J. A. Michiels, C. A. A. van Boeckel, Drug Discovery Today 2003, 8, 297-306;
4. b) M. J. Drysdale, G. Lentzen, N. Matassova, A. I. H. Murchie, F. Aboul-ela, M. Afshar, Prog. Med. Chem. 2002, 39, 73-119;
5. c) J. Gallego, G. Varani, Acc. Chem. Res. 2001, 34, 836-843;
6. d) S. J. Sucheck, C. H. Wong, Curr. Opin. Chem. Biol. 2000, 4, 678-686.
7. T. Hermann, Biopolymers 2003, 70, 4-18.
8. J. Karn, J. Mol. Biol. 1999, 293, 135-154.
9. a) A. Krebs, V. Ludwig, O. Boden, M.-W. Göbel, ChembBioChem 2003, 4, 972-978;
10. b) M. Froeyen, P. Herdewijn, Curr. Top. Med. Chem. 2002, 2, 1123-1145.
11. Z. Du, K. E. Lind, T. L. James, Chem. Biol. 2002, 9, 707-712.
12. E. Byvatov, U. Fechner, J. Sadowsky, G. Schneider, J. Chem. Inf. Comput. Sci. 2003, 43, 1882-1889.
13. M. Mayer, T. L. James, J. Am. Chem. Soc. 2004, 126, 4453-4460.
14. K. E. Lind, Z. Du, K. Fujinaga, B. M. Peterlin, T. L. James, Chem. Biol. 2002, 9, 185-193.
15. a) G. Schneider, H.-J. Böhm, Drug Discovery Today 2002, 7, 64-70;
16. b) Virtual Screening for Bioactive Molecules (Eds.: H.-J. Böhm, G. Schneider) Wiley-VCH, Weinheim, 2000.
17. A. V. Filikov, V. Mohan, T. A. Vickers, R. H. Griffey, P. D. Cook, R. A. Abagyan, T. L. James, J. Comput.-Aided Mol. Des. 2000, 14, 593-610.
18. a) N. Leulliot, G. Varani, Biochemistry 2001, 40, 7947-7956;
19. b) J. R. Williamson, Nat. Struct. Biol. 2000, 7, 834-837.
20. G. Schneider, W. Neidhard, T. Giller, G. Schmid, Angew. Chem. 1999, 111, 3068-3070;
21. Angew. Chem. Int. Ed. 1999, 38, 2894-2896.
22. S. Renner, G. Schneider, J. Med. Chem. 2004, 47, 4653-4664.
23. U. Fechner, L. Franke, S. Renner, P. Schneider, G. Schneider, J. Comput.-Aided Mol. Des. 2003, 17, 687-698.
24. G. Schneider, P. Schneider in Chemogenomics in Drug Discovery (Eds.: H. Kubinyi, G. Müller), Wiley-VCH, Weinheim, 2004, pp. 341-376.
25. Specs, Delftechpark 30, 2628 XH Delft, The Netherlands; http://www.specs.net.
26. MOE, Molecular Operating Environment, version 2004.03, Chemical Computing Group Inc., 1010 Sherbrooke St. West, 910, Montreal, Canada.
27. T. A. Halgren, J. Comput. Chem. 1996, 5 & 6, 490-512.
28. C. Matsumoto, K. Hamasaki, H. Mihara, A. Ueno, Bioorg. Med. Chem. Lett. 2000, 10, 1857-1861.
29. F. Hamy, V. Brondani, A. Florsheimer, W. Stark, M. J. Blommers, T. Klimkait, Biochemistry 1998, 37, 5086-5095.
30. G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, A. J. Olson, J. Comput. Chem. 1998, 19, 1639-1662.
31. C. Detering, G. Varani, J. Med. Chem. 2004, 47, 4188-4201. The authors used a threshold of 2.5 A in their docking study comprising many RNA-ligand complexes. For the TAR-acetylpromazine complex some of the best docking solutions showed an RMSD between 2.0 and 2.5 Å. See Supplementary Information to the reference.
32. P. Schneider, G. Schneider, QSAR Comb. Sci. 2003, 22, 713-718.
33. J. Tao, A. D. Frankel, Proc. Natl. Acad. Sci. USA 1992, 89, 2723-2726.
34. N. Z. Tugusheva, S. Y. Ryabova, N. P. Solov'eva, V. G. Granik, Chem. Heterocycl. Camp. 1998, 34, 216-221.
35. A. K. Shanazarov, V. G. Granik, N. I. Andreeva, S. M. Golovina, M. D. Mashkovskii, Khim.-Farm. Zh. 1989, 23, 1197-1200.